Please assess the completion status of the following clinical trial:

Trial Title: Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants with confirmed diagnosis of CF~* Must have the F508del-CFTR mutation on at least 1 allele.~* FEV1 greater than equal (\>=) 40% of predicted normal for age, gender, and height (Knudson standards)(Cohort 1, 2, and 3); FEV1 40-90% of predicted normal for age, gender, and height (Hankinson standards (Cohort 4)~* Participant of child-bearing potential and who are sexually active must meet the contraception requirements~Exclusion Criteria:~* History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the participant (e.g., cirrhosis with portal hypertension).~* An acute illness including acute upper or lower respiratory infection, pulmonary exacerbation or changes in therapy (including antibiotics) for pulmonary disease within 14 days (Cohort 1, 2, and 3) or 28 days (Cohort 4) before receiving the first dose of study drug.~* History of solid organ or hematological transplantation.~* History of alcohol abuse or drug addiction in the past year, including cannabis, cocaine, and opiates.~* Ongoing participation in another therapeutic clinical study, or prior participation in an investigational drug study without appropriate washout~* Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of non-hormonal contraception~* Participants enrolled in Cohort 1 or Cohort 2 will not be eligible for Cohort 3~* Ongoing or prior participation in an investigational drug study within 30 days of the Screening Visit~* Heterozygous participants who participated in Cohort 2 and meet the eligibility criteria for Cohort 4 may participate in Cohort 4~* Evidence of lens opacity or cataract as determined by the ophthalmologic examination (Cohort 4 only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE) (Type: EXPERIMENTAL): Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
- Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO) (Type: EXPERIMENTAL): Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
- Cohort 4: Placebo (Type: PLACEBO_COMPARATOR): Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).
- Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h (Type: EXPERIMENTAL): Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).
- Cohort 1: Placebo (Type: PLACEBO_COMPARATOR): Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).
- Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h (Type: EXPERIMENTAL): Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).
- Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (Type: EXPERIMENTAL): Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).
- Cohort 2 and 3: Placebo (HO and HE) (Type: PLACEBO_COMPARATOR): Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).
- Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO) (Type: EXPERIMENTAL): Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
- Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO) (Type: EXPERIMENTAL): Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).

Based on this trial design, predict the completion outcome and termination type (if applicable).